Does novel coronavirus infection increase the risk of chronic systemic hyperinflammation and low-grade systemic inflammation in patients with pulmonary tuberculosis?
- Authors: Sabadash E.V.1, Zhuravleva Y.A.2, Skornyakov S.N.1, Gusev E.Y.2, Zotova N.V.2, Ershova A.V.1, Yarkieva A.A.3
-
Affiliations:
- Ural Research Institute of Phthisiopulmonology, Branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases
- Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
- Ural State Medical University
- Issue: Vol 28, No 1 (2025)
- Pages: 65-72
- Section: SHORT COMMUNICATIONS
- URL: https://bakhtiniada.ru/1028-7221/article/view/277344
- DOI: https://doi.org/10.46235/1028-7221-16989-DNC
- ID: 277344
Cite item
Full Text
Abstract
The development of new coronavirus infectious disease (COVID-19) is associated with an increase in the pro-inflammatory and pro-thrombotic potential of microvascular endothelium. A specific feature of SARS-CoV-2 infection is the post-COVID syndrome that is characterised by long-term impairment of various organs and systems. The immune pathogenesis of post-COVID syndrome in patients with pulmonary tuberculosis requires special attention due to their baseline pro-inflammatory status. The objective of this study was to evaluate the effect of novel coronavirus infection on the risk of chronic systemic hyper-inflammation and low-grade systemic inflammation in patients with pulmonary tuberculosis.
Two main groups consisted of patients with pulmonary tuberculosis who had survived COVID-19 (mild form) 3 months ago, or at earlier terms, including the subjects with post-COVID symptoms and those free of these symptoms. The comparison group included patients with pulmonary tuberculosis without a history of COVID-19. The control group was presented by healthy blood donors. Concentrations of IL-6, IL-10, tumor necrosis factor alpha (TNFá), D-dimers, troponin I, cortisol, and endothelin I (ET-I) were measured in patients’ plasma by immunoassay technique. On the basis of these markers, we calculated integral indices of systemic inflammatory response (SIR) – the levels of reactivity (RL), and chronic systemic hyper-inflammation (ChSI). Low-grade systemic inflammation (LGSI) was diagnosed in absence of ChSI, but in cases of simultaneous increase of D-dimer levels > 250 ng/ml and ET-I levels > 90 pg/ml in the patient.
The most prevalent symptoms of post-COVID in patients with pulmonary tuberculosis were tachycardia, arthralgia, and chronic fatigue syndrome, which correspond to the population-wide data. By all empirical parameters, the groups of tuberculosis patients were comparable to each other (p > 0.05) and significantly differed from control group. However, evaluation of integral indexes is more crucial for assessing the ‘systemic’ origin of the process. Thus, 23-50% of patients with pulmonary tuberculosis developed subcritical SIR (RL = 1-2), being a feature of ChSI in 7.1-13.6% of cases (both in COVID-19 reconvalescents and non-COVID-19 patients). Meanwhile, all patient groups did not show significant difference in the frequency of LGSI and endothelial dysfunction (p > 0.05). However, there was a trend towards an increase of these scores in the following sequence: tuberculosis without COVID-19 – tuberculosis + COVID-19 – tuberculosis + COVID-19 + post-COVID syndrome.
Most patients with pulmonary tuberculosis are not characterized by the development of chronic systemic hyperinflammation. LGSI is the most probable feature of general pathology in tuberculosis infection. Tuberculosis infection sufficiently contributes to the development of LGSI, since the frequency and severity of LGSI and its individual manifestations are independent on the new coronavirus infection and signs of post-COVID syndrome.
Full Text
##article.viewOnOriginalSite##About the authors
E. V. Sabadash
Ural Research Institute of Phthisiopulmonology, Branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases
Email: jazhur@mail.ru
PhD (Medicine), Head, Research and Clinical Laboratory of Combined Socially Significant Diseases
Russian Federation, YekaterinburgY. A. Zhuravleva
Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
Author for correspondence.
Email: jazhur@mail.ru
PhD (Biology), Senior Research Associate, Laboratory of Inflammation Immunology
Russian Federation, YekaterinburgS. N. Skornyakov
Ural Research Institute of Phthisiopulmonology, Branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases
Email: jazhur@mail.ru
PhD, MD (Medicine), Head, Research Department
Russian Federation, YekaterinburgE. Y. Gusev
Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
Email: jazhur@mail.ru
PhD, MD (Medicine), Professor, Head, Laboratory of Inflammation Immunology
Russian Federation, YekaterinburgN. V. Zotova
Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
Email: jazhur@mail.ru
PhD (Biology), Senior Research Associate, Laboratory of Inflammation Immunology
Russian Federation, YekaterinburgA. V. Ershova
Ural Research Institute of Phthisiopulmonology, Branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases
Email: jazhur@mail.ru
PhD (Biology), Research Associate, Research Department of Microbiology and Preclinical Research
Russian Federation, YekaterinburgA. A. Yarkieva
Ural State Medical University
Email: jazhur@mail.ru
Medical Resident, Department of Infectious Diseases, Phthisiology and Pulmonology
Russian Federation, YekaterinburgReferences
- Власов Т.Д., Нестерович И.И., Шиманьски Д.А. Эндотелиальная дисфункция: от частного к общему. Возврат к «старой парадигме»? // Регионарное кровообращение и микроциркуляция, 2019. Т. 8, № 2. С. 19-27. [Vlasov T.D., Nesterovich I.I., Shimanski D.A. Endothelial Dysfunction: from the Particular to the General. Return to the “Old Paradigm”? Regionarnoe krovoobrashchenie i mikrotsirkulyatsiya = Regional Hemodynamics and Microcirculation, 2019, Vol. 18, no. 2, pp. 19-27. (In Russ.)]
- Добрынина М.А., Зурочка А.В., Комелькова М.В., Зурочка В.А., Праскурничий Е.А., Рябова Л.В., Сарапульцев А.П. Изменения врожденных факторов иммунной системы по данным изучения иммунной системы периферической крови у постковидных пациентов // Инфекция и иммунитет, 2023. Т. 13, № 5. C. 864-872. [Dobrynina M.A., Zurochka A.V., Komelkova M.V., Zurochka V.A., Praskurnichiy E.A., Ryabova L.V., Sarapultsev A.P. Alteration in innate immune cues assessed by analyzing peripheral blood immune system in post-COVID patients. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2023, Vol. 13, no. 5, pp. 864-872. (In Russ.)] doi: 10.15789/2220-7619-AII-9641.
- Мухоморова Л.В., Вельков В.В. Постковидный синдром – длинный КОВИД. Патофизиология, риски, биомаркеры, диагноз, прогноз // Лабораторная и клиническая медицина. Фармация, 2022. Т. 2, № 3. С. 57-64. [Mukhomorova L.V., Velkov V.V. Postcovid syndrome – long COVID. Pathophysiology, risks, biomarkers, diagnosis, prognosis . Laboratornaya i klinicheskaya meditsina. Farmatsiya = Laboratory and Clinical Medicine. Pharmacy, 2022, Vol. 2, no. 3, pp. 57-64. (In Russ.)]
- Сабадаш Е.В., Скорняков С.Н., Медвинский И.Д., Красноборова С.Ю., Бурылова Е.А., Телицина Э.В. Оптическая когерентная томография: новые возможности выявления доклинической патологии органа зрения у пациентов с ВИЧ-инфекцией и туберкулезом // Туберкулёз и болезни лёгких, 2021. Т. 99, № 4. С. 44-50. [Sabadash E.V., Skornyakov S.N., Medvinskiy I.D., Krasnoborova S.Yu., Burylova E.А., Telitsina E.V. Optical coherence tomography: new opportunities for detecting preclinical vision disorders in patients with HIV infection and tuberculosis. Tuberkulioz i bolezni liogkikh = Tuberculosis and Lung Diseases, 2021, Vol. 99, no. 4, pp. 44-50 (In Russ.)]
- Amaral E.P., Vinhaes C.L., Oliveira-de-Souza D., Nogueira B., Akrami K.M., Andrade B.B. The interplay between systemic inflammation, oxidative stress, and tissue remodeling in tuberculosis. Antioxid. Redox Signal., 2021, Vol. 34, no. 6, pp. 471-485.
- González-Domenech C.M., Pérez-Hernández I., Gómez-Ayerbe C., Viciana Ramos I., Palacios-Muñoz R., Santos J. A pandemic within other pandemics. When a multiple infection of a host occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis. Viruses, 2021, Vol. 13, no. 5, 931. doi: 10.3390/v13050931.
- Gusev E., Zhuravleva Y. Inflammation: A new look at an old problem. Int. J. Mol. Sci., 2022, Vol. 23, no. 9, 4596. doi: 10.3390/ijms23094596.
- Jensterle M., Herman R., Janež A., Mahmeed W.A., Al-Rasadi K., Al-Alawi K., Banach M., Banerjee Y., Ceriello A., Cesur M., Cosentino F., Galia M., Goh S.Y., Kalra S., Kempler P., Lessan N., Lotufo P., Papanas N., Rizvi A.A., Santos R.D., Stoian A.P., Toth P.P., Viswanathan V., Rizzo M. The Relationship between COVID-19 and hypothalamic–pituitary–adrenal axis: a large spectrum from glucocorticoid insufficiency to excess – the CAPISCO International Expert Panel. Int. J. Mol. Sci., 2022, Vol. 23, no. 13, 7326. doi: 10.3390/ijms23137326.
- Kervevan J., Staropoli I., Slama D., Jeger-Madiot R., Donnadieu F., Planas D., Pietri M.P., Loghmari-Bouchneb W., Alaba Tanah M., Robinot R., Boufassa F., White M., Salmon-Ceron D., Chakrabarti L.A. Divergent adaptive immune responses define two types of long COVID. Front. Immunol., 2023, Vol. 14, 1221961. doi: 10.3389/fimmu.2023.1221961.
- Kopp L., Schweinlin A., Tingö L., Hutchinson A.N., Feit V., Jähnichen T., Lehnert K., Vetter W., Rings A., Jensen M.G., Brummer R.J., Bischoff S.C. Potential modulation of inflammation and physical function by combined probiotics, omega-3 supplementation and vitamin D supplementation in overweight/obese patients with chronic low-grade inflammation: a randomized, placebo-controlled trial. Int. J. Mol. Sci., 2023, Vol. 24, no. 10, 8567. doi: 10.3390/ijms24108567.
- Ramakrishnan R.K., Kashour T., Hamid Q., Halwani R., Tleyjeh I.M. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front. Immunol., 2021, Vol. 12, 686029. doi: 10.3389/fimmu.2021.686029.
- Stein S.R., Ramelli S.C., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C.W., Sun J., Dickey J.M., Ylaya K., Ko S.H., Platt A.P., Burbelo P.D., Quezado M., Pittaluga S., Purcell M., Munster V.J., Belinky F., Ramos-Benitez M.J., Boritz E.A., Lach I.A., Herr D.L., Rabin J., Saharia K.K., Madathil R.J., Tabatabai A., Soherwardi S., McCurdy M.T., NIH COVID-19 Autopsy Consortium, Peterson K.E., Cohen J.I., de Wit E., Vannella K.M., Hewitt S.M., Kleiner D.E., Chertow D.S. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022, Vol. 612, no. 7941, pp. 758-763.
- Sunada N., Honda H., Nakano Y., Yamamoto K., Tokumasu K., Sakurada Y., Matsuda Y., Hasegawa T., Otsuka Y., Obika M., Hanayama Y., Hagiya H., Ueda K., Kataoka H., Otsuka F. Hormonal trends in patients suffering from long COVID symptoms. Endocr. J., 2022, Vol. 69, no. 10, pp. 1173-1181.
- Xu S.W., Ilyas I., Weng J.P. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin., 2023, Vol. 44, no. 4, pp. 695-709.
- Zotova N., Zhuravleva Y., Chereshnev V., Gusev E. Acute and chronic systemic inflammation: features and differences in the pathogenesis, and integral criteria for verification and differentiation. Int. J. Mol. Sci., 2023, Vol. 24, no. 2, 1144. doi: 10.3390/ijms24021144.
Supplementary files
